SPIRIVA
What it isLong-acting muscarinic antagonist bronchodilator; COPD maintenance and add-on asthma treatment.
Why this oneIt has the longest clinical track record among LAMAs, and its soft-mist formulation also carries an asthma indication.
What limits itDry mouth, urinary retention, and glaucoma can worsen; it is maintenance only, and powder capsules must be inhaled, not swallowed.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| COPD, maintenance | Adults | Two inhalations of one 18 mcg capsule QD | 18 mcg QD |
Renal No adjustment needed; monitor closely for anticholinergic effects if CrCl <60 mL/min
Hepatic No adjustment needed (not studied)
Do not exceed one dose (two inhalations) per 24 hours
Pregnancy Limited human data insufficient to inform risk
Lactation No human data; present in milk of lactating rats
NO BOXED WARNINGS
Principal riskAnticholinergic effects; acute urinary retention
Cost, est. cash$30–$500/month
Generic entry2023
Legacy pregnancy categoryC
Defining liabilityTremor, tachycardia or anticholinergic effects; excessive beta-agonist exposure can cause hypokalemia and arrhythmia.

Open Tiotropium in the interactive console ↗
